Table 2. The clinicopathological characteristics related to the expression of ERAP2 in 157 samples of OSCCs.
| Characteristics | Case number | IHC score (Mean ± SD) | P value |
|---|---|---|---|
| Sex | |||
| Male | 137 | 160.3 ± 78.7 | 0.158 |
| Female | 20 | 134.3 ± 79.4 | |
| Age (year) | |||
| < 49.8 | 78 | 147.9 ± 80.3 | 0.084 |
| ≥ 49.8 | 79 | 166.0 ± 77.1 | |
| T classification | |||
| T1-T2 | 83 | 148.1 ± 84.7 | 0.080 |
| T3-T4 | 74 | 167.0 ± 71.4 | |
| N classification | |||
| N = 0 | 101 | 147.8 ± 78.7 | 0.041† |
| N > 0 | 56 | 173.7 ± 77.5 | |
| Overall stage | |||
| I-II | 59 | 139.8 ± 82.0 | 0.015† |
| III-IV | 98 | 167.4 ± 75.7 | |
| Extracapsular spread | |||
| No | 129 | 153.2 ± 80.1 | 0.132 |
| Yes | 28 | 177.5 ± 71.3 | |
| Differentiation | |||
| W-D + M-D | 144 | 157.7 ± 77.7 | 0.969 |
| P-D | 13 | 150.0 ± 95.3 | |
| Perineural invasion | |||
| negative | 112 | 146.6 ± 79.7 | 0.010† |
| positive | 44 | 182.7 ± 72.4 | |
| Tumor depth | |||
| < 8mm (median) | 84 | 145.8 ± 82.6 | 0.032† |
| ≥ 8mm | 72 | 169.5 ± 73.4 | |
†statistically significant. IHC, immunohistochemical; SD, standard deviation; M-D, moderately differentiated; P-D, poorly differentiated; W-D, well-differentiated